medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2023, Número 1

<< Anterior Siguiente >>

Medicina & Laboratorio 2023; 27 (1)


Virus de Epstein-Barr: más que una mononucleosis infecciosa

Toro-Montoya AI

Idioma: Español
Referencias bibliográficas: 56
Paginas: 51-64
Archivo PDF: 201.87 Kb.


RESUMEN

El virus de Epstein-Barr (VEB) fue el primer virus asociado a neoplasias en humanos. Infecta el 95 % de la población mundial, y aunque usualmente es asintomático, puede causar mononucleosis infecciosa y se relaciona con más de 200.000 casos de neoplasias al año. De igual forma, se asocia con esclerosis múltiple y otras enfermedades autoinmunes. A pesar de ser catalogado como un virus oncogénico, solo un pequeño porcentaje de los individuos infectados desarrollan neoplasias asociadas a VEB. Su persistencia involucra la capacidad de alternar entre una serie de programas de latencia, y de reactivarse cuando tiene la necesidad de colonizar nuevas células B de memoria, con el fin de sostener una infección de por vida y poder transmitirse a nuevos hospederos. En esta revisión se presentan las generalidades del VEB, además de su asociación con varios tipos de neoplasias, como son el carcinoma nasofaríngeo, el carcinoma gástrico, el linfoma de Hodgkin y el linfoma de Burkitt, y la esclerosis múltiple. Adicionalmente, se describen los mecanismos fisiopatológicos de las diferentes entidades, algunos de ellos no completamente dilucidados.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Wong Y, Meehan MT, Burrows SR, DoolanDL, Miles JJ. Estimating the global burden ofEpstein-Barr virus-related cancers. J CancerRes Clin Oncol 2022;148:31-46. https://doi.org/10.1007/s00432-021-03824-y.

  2. Damania B, Kenney SC, Raab-Traub N.Epstein-Barr virus: Biology and clinical disease.Cell 2022;185:3652-3670. https://doi.org/10.1016/j.cell.2022.08.026.

  3. Fugl A, Andersen CL. Epstein-Barr virus and itsassociation with disease - a review of relevanceto general practice. BMC Fam Pract 2019;20:62.https://doi.org/10.1186/s12875-019-0954-3.

  4. Münz C. Latency and lytic replication inEpstein-Barr virus-associated oncogenesis. NatRev Microbiol 2019;17:691-700. https://doi.org/10.1038/s41579-019-0249-7.

  5. Patel PD, Alghareeb R, Hussain A, MaheshwariMV, Khalid N. The association of Epstein-Barr virus with cancer. Cureus 2022;14:e26314.https://doi.org/10.7759/cureus.26314.

  6. Läderach F, Münz C. Altered immune responseto the Epstein-Barr virus as a prerequisite formultiple sclerosis. Cells 2022;11:2757. https://doi.org/10.3390/cells11172757.

  7. Guo R, Gewurz BE. Epigenetic control ofthe Epstein-Barr lifecycle. Curr Opin Virol2022;52:78-88. https://doi.org/10.1016/j.coviro.2021.11.013.

  8. Hau PM, Lung HL, Wu M, Tsang CM, WongKL, Mak NK, et al. Targeting Epstein-Barr virusin nasopharyngeal carcinoma. Front Oncol2020;10:600. https://doi.org/10.3389/fonc.2020.00600.

  9. Soldan SS, Lieberman PM. Epstein-Barr virusand multiple sclerosis. Nat Rev Microbiol2022; 1-14. [Epub ahead of print] 5 de agostode 2022. https://doi.org/10.1038/s41579-022-00770-5.

  10. Albanese M, Tagawa T, HammerschmidtW. Strategies of Epstein-Barr virus to evadeinnate antiviral immunity of its human host.Front Microbiol 2022;13:955603. https://doi.org/10.3389/fmicb.2022.955603.

  11. Weidner-Glunde M, Kruminis-Kaszkiel E,Savanagouder M. Herpesviral latency-commonthemes. Pathogens 2020;9:125. https://doi.org/10.3390/pathogens9020125.

  12. Frappier L. Epstein-Barr virus: Current questionsand challenges. Tumour Virus Res2021;12:200218. https://doi.org/10.1016/j.tvr.2021.200218.

  13. Di Pietro A. Epstein-Barr virus promotes B celllymphomas by manipulating the host epigeneticmachinery. Cancers (Basel) 2020;12:3037.https://doi.org/10.3390/cancers12103037.

  14. Houen G, Trier NH, Frederiksen JL. Epstein-Barr virus and multiple sclerosis. Front Immunol2020;11:587078. https://doi.org/10.3389/fimmu.2020.587078.

  15. Yang J, Liu Z, Zeng B, Hu G, Gan R. Epstein-Barr virus-associated gastric cancer: A distinctsubtype. Cancer Lett 2020;495:191-199.https://doi.org/10.1016/j.canlet.2020.09.019.

  16. Pagano JS, Whitehurst CB, Andrei G. Antiviraldrugs for EBV. Cancers (Basel) 2018;10:197.https://doi.org/10.3390/cancers10060197.

  17. Chijioke O, Landtwing V, Münz C. NK cellinfluence on the outcome of primary Epstein-Barr virus infection. Front Immunol 2016;7:323.https://doi.org/10.3389/fimmu.2016.00323.

  18. Wen KW, Wang L, Menke JR, Damania B.Cancers associated with human gammaherpesviruses.FEBS J 2022. https://doi.org/10.1111/febs.16206.

  19. Bakkalci D, Jia Y, Winter JR, Lewis JE, TaylorGS, Stagg HR. Risk factors for Epstein Barr virus-associated cancers: a systematic review, criticalappraisal, and mapping of the epidemiologicalevidence. J Glob Health 2020;10:010405.https://doi.org/10.7189/jogh.10.010405.

  20. de Martel C, Georges D, Bray F, Ferlay J,Clifford GM. Global burden of cancer attributableto infections in 2018: a worldwideincidence analysis. Lancet Glob Health2020;8:e180-e190. https://doi.org/10.1016/s2214-109x(19)30488-7.

  21. Guikema JE, Schuuring E, Kluin PM. Structureand consequences of IGH switch breakpointsin Burkitt lymphoma. J Natl Cancer Inst Monogr2008:32-36. https://doi.org/10.1093/jncimonographs/lgn020.

  22. Carpenter LM, Newton R, Casabonne D, ZieglerJ, Mbulaiteye S, Mbidde E, et al. Antibodiesagainst malaria and Epstein-Barr virusin childhood Burkitt lymphoma: a case-controlstudy in Uganda. Int J Cancer 2008;122:1319-1323. https://doi.org/10.1002/ijc.23254.

  23. World Health Organization (WHO). The GlobalCancer Observatory (Globocan). Ginebra,Suiza: WHO; 2020. Acceso 23 de septiembrede 2022. Disponible en https://gco.iarc.fr/today/data/factsheets/populations/900-worldfact-sheets.pdf.

  24. Murray PG, Young LS. An etiological rolefor the Epstein-Barr virus in the pathogenesisof classical Hodgkin lymphoma. Blood2019;134:591-596. https://doi.org/10.1182/blood.2019000568.

  25. Gopas J, Stern E, Zurgil U, Ozer J, Ben-AriA, Shubinsky G, et al. Reed-Sternberg cells inHodgkin's lymphoma present features of cellularsenescence. Cell Death Dis 2016;7:e2457.https://doi.org/10.1038/cddis.2016.185.

  26. Habeeb R, Al Hafar L, Monem F. EBV plasmaEpstein-Barr virus (EBV) DNA as a biomarkerfor diagnosis of EBV-positive hodgkin lymphomain Syria. J Infect Dev Ctries 2021;15:1917-1922. https://doi.org/10.3855/jidc.14919.

  27. Spacek M, Hubacek P, Markova J, Zajac M,Vernerova Z, Kamaradova K, et al. PlasmaEBV-DNA monitoring in Epstein-Barr viruspositiveHodgkin lymphoma patients. Apmis2011;119:10-16. https://doi.org/10.1111/j.1600-0463.2010.02685.x.

  28. Wang C, Zou SP, Chen DG, Wang JS, ZhengYB, Chen XR, et al. Latent Epstein-Barr virusinfection status and prognosis in patientswith newly diagnosed Hodgkin lymphoma inSoutheast China: a single-center retrospectivestudy. Hematology 2021;26:675-683. https://doi.org/10.1080/16078454.2021.1971864.

  29. Martelli M, Ferreri AJ, Agostinelli C, Di RoccoA, Pfreundschuh M, Pileri SA. Diffuse largeB-cell lymphoma. Crit Rev Oncol Hematol2013;87:146-171. https://doi.org/10.1016/j.critrevonc.2012.12.009.

  30. Malpica L, Marques-Piubelli ML, Beltran BE,Chavez JC, Miranda RN, Castillo JJ. EBVpositivediffuse large B-cell lymphoma, nototherwise specified: 2022 update on diagnosis,risk-stratification, and management.Am J Hematol 2022;97:951-965. https://doi.org/10.1002/ajh.26579.

  31. Hwang J, Suh CH, Won Kim K, Kim HS,Armand P, Huang RY, et al. The incidenceof Epstein-Barr virus-positive diffuse largeB-cell lymphoma: A systematic review andmeta-analysis. Cancers (Basel) 2021;13:1785.https://doi.org/10.3390/cancers13081785.

  32. Syrykh C, Péricart S, Lamaison C, EscudiéF, Brousset P, Laurent C. Epstein-Barr virusassociatedT- and NK-cell lymphoproliferativediseases: A review of clinical and pathologicalfeatures. Cancers (Basel) 2021;13:3315.https://doi.org/10.3390/cancers13133315.

  33. Hue SS, Oon ML, Wang S, Tan SY, Ng SB.Epstein-Barr virus-associated T- and NK-cell lymphoproliferativediseases: an update and diagnosticapproach. Pathology 2020;52:111-127.https://doi.org/10.1016/j.pathol.2019.09.011.

  34. Fox CP, Civallero M, Ko YH, Manni M, SkrypetsT, Pileri S, et al. Survival outcomes of patientswith extranodal natural-killer T-cell lymphoma:a prospective cohort study from theinternational T-cell Project. Lancet Haematol2020;7:e284-e294. https://doi.org/10.1016/s2352-3026(19)30283-2.

  35. Banko A, Miljanovic D, Lazarevic I, CirkovicA. A systematic review of Epstein-Barr viruslatent membrane protein 1 (LMP1) gene variantsin nasopharyngeal carcinoma. Pathogens2021;10:1057. https://doi.org/10.3390/pathogens10081057.

  36. Tsao SW, Tsang CM, Lo KW. Epstein-Barrvirus infection and nasopharyngeal carcinoma.Philos Trans R Soc Lond B Biol Sci2017;372:20160270. https://doi.org/10.1098/rstb.2016.0270.

  37. Shao JY, Li YH, Gao HY, Wu QL, Cui NJ,Zhang L, et al. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulinA/virus capsid antigen antibodytiters in patients with nasopharyngeal carcinoma.Cancer 2004;100:1162-1170. https://doi.org/10.1002/cncr.20099.

  38. Alruwaii ZI, Montgomery EA. Select Epstein-Barr virus-associated digestive tract lesions forthe practicing pathologist. Arch Pathol Lab Med2021;145:562-570. https://doi.org/10.5858/arpa.2019-0703-RA.

  39. Tavakoli A, Monavari SH, Solaymani-MohammadiF, Kiani SJ, Armat S, FarahmandM. Association between Epstein-Barr virus infectionand gastric cancer: a systematic reviewand meta-analysis. BMC Cancer 2020;20:493.https://doi.org/10.1186/s12885-020-07013-x.

  40. Hirabayashi M, Georges D, Clifford GM,de Martel C. Estimating the global burdenof Epstein-Barr virus-associated gastric cancer:A systematic review and meta-analysis.Clin Gastroenterol Hepatol 2022. https://doi.org/10.1016/j.cgh.2022.07.042.

  41. Armenta-Quiroga AS, Khalid R, Dhalla PS,Garcia J, Bapatla A, Kaul A, et al. Essential genes to consider in Epstein-Barr virus-associatedgastric cancer: A systematic review. Cureus2020;12:e11610. https://doi.org/10.7759/cureus.11610.

  42. Stanland LJ, Luftig MA. The role of EBV-inducedhypermethylation in gastric cancer tumorigenesis.Viruses 2020;12:1222. https://doi.org/10.3390/v12111222.

  43. Strong MJ, Xu G, Coco J, Baribault C, VinayDS, Lacey MR, et al. Differences ingastric carcinoma microenvironment stratifyaccording to EBV infection intensity: implicationsfor possible immune adjuvant therapy.PLoS Pathog 2013;9:e1003341. https://doi.org/10.1371/journal.ppat.1003341.

  44. Pyo JS, Kim NY, Kang DW. Clinicopathologicalsignificance of EBV-infected gastric carcinomas:A meta-analysis. Medicina (Kaunas)2020;56:345. https://doi.org/10.3390/medicina56070345.

  45. Houen G, Trier NH. Epstein-Barr virus andsystemic autoimmune diseases. Front Immunol2020;11:587380. https://doi.org/10.3389/fimmu.2020.587380.

  46. Robinson WH, Steinman L. Epstein-Barr virusand multiple sclerosis. Science 2022;375:264-265. https://doi.org/10.1126/science.abm7930.

  47. Balandraud N, Roudier J. Epstein-Barr virusand rheumatoid arthritis. Joint Bone Spine2018;85:165-170. https://doi.org/10.1016/j.jbspin.2017.04.011.

  48. Bar-Or A, Pender MP, Khanna R, SteinmanL, Hartung HP, Maniar T, et al. Epstein-Barrvirus in multiple sclerosis: Theory and emergingimmunotherapies. Trends Mol Med2020;26:296-310. https://doi.org/10.1016/j.molmed.2019.11.003.

  49. Bjornevik K, Cortese M, Healy BC, Kuhle J, MinaMJ, Leng Y, et al. Longitudinal analysis revealshigh prevalence of Epstein-Barr virus associatedwith multiple sclerosis. Science 2022;375:296-301. https://doi.org/10.1126/science.abj8222.

  50. Aloisi F, Salvetti M. Epstein-Barr virus andmultiple sclerosis: supporting causality. LancetNeurol 2022;21:300-301. https://doi.org/10.1016/s1474-4422(22)00086-2.

  51. Wekerle H. Epstein-Barr virus sparks brainautoimmunity in multiple sclerosis. Nature2022;603:230-232. https://doi.org/10.1038/d41586-022-00382-2.

  52. Jacobs BM, Giovannoni G, Cuzick J, DobsonR. Systematic review and meta-analysisof the association between Epstein-Barr virus,multiple sclerosis and other risk factors.Mult Scler 2020;26:1281-1297. https://doi.org/10.1177/1352458520907901.

  53. Hammami MB, Aboushaar R, Musmar A, HammamiS. Epstein-Barr virus-associated acutepancreatitis. BMJ Case Rep 2019;12:e231744.https://doi.org/10.1136/bcr-2019-231744.

  54. Osorio JC, Blanco R, Corvalán AH, MuñozJP, Calaf GM, Aguayo F. Epstein-Barr virusinfection in lung cancer: Insights and perspectives.Pathogens 2022;11:132. https://doi.org/10.3390/pathogens11020132.

  55. Oleynikova NA, Danilova NV, Grimuta MO,Malkov PG. Epstein-Barr virus in the developmentof colorectal cancer (review). SovremTekhnologii Med 2021;13:82-91. https://doi.org/10.17691/stm2021.13.4.09.

  56. Zhang N, Zuo Y, Jiang L, Peng Y, Huang X,Zuo L. Epstein-Barr virus and neurologicaldiseases. Front Mol Biosci 2021;8:816098.https://doi.org/10.3389/fmolb.2021.816098.




2020     |     www.medigraphic.com